1431771-83-3

Basic information

• Product Name: C₃₀H₄₄O₁₁S
• CAS NO: 1431771-83-3
• Molecular Weight: 612.739
• Mol File: 1431771-83-3.mol

Chemical Properties

• CAS DataBase Reference: C₃₀H₄₄O₁₁S(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₀H₄₄O₁₁S(1431771-83-3)
• EPA Substance Registry System: C₃₀H₄₄O₁₁S(1431771-83-3)

Safety Data

• Hazardous Substances Data: 1431771-83-3(Hazardous Substances Data)

Upstream product

• 1431771-81-1 C₃₅H₅₆O₉Si 
• 1431771-80-0 C₂₉H₅₀O₆Si 
• 1431771-82-2 C₂₉H₄₂O₉ 
• 124-63-0 methanesulfonyl chloride 
• 1318910-22-3 1-deoxy-1-{4-methoxy-3-[(trans-4-n-propylcyclohexyl)methyl]phenyl}-β-D-glucose 

Downstream Products

• 1431771-84-4 C₂₉H₄₁N₃O₈ 
• 1431771-61-7 C₂₃H₃₅N₃O₅ 
• 1431771-93-5 C₃₂H₄₅N₃O₉ 
• 1431771-71-9 C₂₆H₃₉N₃O₆ 

Relevant articles and documents

Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors

Seven cyclohexane-bearing C-glucoside derivatives (7, 9, 12, 13 and 17-19) were designed and synthesized as SGLT2 inhibitors starting from a potent SGLT2 inhibitor we discovered in earlier work, (1S)-1-deoxy-1-[4-methoxy-3-(trans-n- propylcyclohexyl)methylphenyl]-d-glucose (1). The in vitro and in vivo biological activities were evaluated by hSGLT2/hSGLT1 inhibition and urinary glucose excretion (UGE), respectively. Among the synthesized compounds 12, the 6-deoxy derivative of 1 was the most active and selective SGLT2 inhibitor (IC50 = 1.4 nmol/L against hSGLT2; selectivity = 1576). Compound 12 was a potent SGLT2 inhibitor, which could induce more urinary glucose than 1 and dapagliflozin in UGE.